1929	Kamejiro Shimomura begins producing over-the-counter medicines in Toyama City, and selling them at pharmacies and drugstores throughout Japan.
1954	Takaharu Shimomura establishes Shimomura Yoshindo in Sanno-machi, Toyama City, and begins the contracted manufacture of medicines.
1962	Shimomura Yoshindo is reorganized and established as a joint-stock company, and relocates to Shinjo-machi, Toyama City. Takaharu Shimomura assumes presidency of the company.
1967	A new company factory is constructed.
1970	Company name is changed to Yoshindo Inc.
1973	Production of Chlorella and other health foods begins.
1976	Health food manufacturing section is separated from the company and established as Shinwa Pharmaceuticals Inc. Operations are focused on the contracted manufacture and sale of prescription drugs.
1979	Begins exporting to Taiwan.
1983	Kenzo Shimomura assumes the presidency. Takaharu Shimomura becomes Chairman.
1985	Assists operation of Kenyu Pharmaceuaticals Inc., and strengthens sales.
1986	The Fuchu factory is constructed.
1994	Merges Kenyu Pharmaceuticals Inc.
1995	Capital increased to ¥295,760,000.
1996	New factory in Fuchu-machi completed. Capital increased to ¥406,960,000.
2003	Land is acquired for factory construction (21,933m2). Total area of company land rises to 31,850m2. Factory enlarged by 1,988m2. Total floor area rises to 9,888m2.
2004	Merges YIC Inc., a group of pharmaceutical ingredient manufacturing companies.
2006	Research laboratory is completed.
2007	The affiliated company Soken Inc. changes their name to Labre Soken, Inc.
2009	Capital is reduced to ¥300,000,000.
2010	Bulk drug factory completed. Operations begin.
2011	Pharmaceutical production factory No. 2 completed. Operations begin.
2013	AY Pharmaceuticals Co., Ltd. established as a joint venture. Expands field of business and begins sales of transfusion and dialysis products as well as GE products. Introduction of new Tokyo office and branch office system.
2014	YL Biologics Ltd. established as a joint venture. Biosimilar development begins. Research building No. 2 completed.
2015	Pharmaceutical production factory No. 5 completed. Start of operation.
2016	Established Yoshindo Holdings Co., Ltd. as the group's controlling company. Became a 100% subsidiary of Yoshindo Holdings Co., Ltd. Transferred the mail-order business of Lovere Souken Co., Ltd. to Shinwa Pharmaceutical Co., Ltd. Made AY Pharma Co., Ltd. a 100% subsidiary. Kenzo Shimomura is appointed as Representative Director and Chairman. Hiroki Kitamura was appointed as representative director and president.
2017	Capital was reduced to 100 million yen. Administration building completed.
2019	YL Biologics Co., Ltd. receives approval to manufacture and sell biosimilars.
2020	Chemical Bio Research Co., Ltd. was established as a 100% subsidiary of Yoshindo Holdings Co., Ltd.